Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Never Boring

<< Previous

Bullboard Posts

Next >>

Comment by MasterAlgaeon Oct 22, 2020 10:21am

193 Views

Post# 31761556

RE:RE:RE:RE:RE:RE:RE:RE:Never Boring

The NATIONAL BUREAU OF ECONOMIC RESEARCH in Cambridge Mass published a report in September whcih claims "The U.S. fiscal policy response implemented in the Spring of 2020 (CARES Act) succeeded in mitigating economic welfare losses by around 20% on average[...]"

Popular headlines are focused on 'stimulis concerns'
Will there be a 'stimulis'? We might need more printing machines...

Since the CARES Act at the end of March the Dow is up over 24%

<< Previous

Bullboard Posts

Next >>

Drilling company poised to capitalize on market conditions